CEMIP Antibody (3C12): sc-293483

CEMIP Antibody (3C12) is a mouse monoclonal IgG2a kappa light chain antibody that detects CEMIP protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-CEMIP antibody (3C12) is available as the non-conjugated format. CEMIP, also known as KIAA1199, plays a crucial role in the regulation of extracellular matrix remodeling and is implicated in various pathological processes, including cancer progression and fibrosis. CEMIP′s ability to modulate matrix metalloproteinases highlights its importance in tissue homeostasis and repair. Dysregulation of CEMIP expression has been associated with several diseases, making CEMIP a potential biomarker for diagnosis and a target for therapeutic intervention. CEMIP is primarily localized in the cytoplasm, where CEMIP interacts with other proteins involved in cellular signaling pathways, further emphasizing CEMIP′s significance in maintaining cellular functions. With versatile applications in research, CEMIP monoclonal antibody (3C12) serves as an essential tool for scientists studying CEMIP′s intricate roles in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CEMIP Antibody (3C12) References:

1. Prediction of the coding sequences of unidentified human genes. XV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.  |  Nagase, T., et al. 1999. DNA Res. 6: 337-45. PMID: 10574462
2. Identification of CRYM as a candidate responsible for nonsyndromic deafness, through cDNA microarray analysis of human cochlear and vestibular tissues.  |  Abe, S., et al. 2003. Am J Hum Genet. 72: 73-82. PMID: 12471561
3. Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters' cells and the fibrocytes, as the cause of nonsyndromic hearing loss.  |  Abe, S., et al. 2003. J Hum Genet. 48: 564-70. PMID: 14577002
4. Diagnosis and management of patients with Marfan syndrome.  |  Midla, GS. 2008. JAAPA. 21: 21-5. PMID: 18323350
5. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.  |  Daub, H., et al. 2008. Mol Cell. 31: 438-48. PMID: 18691976
6. Angelman syndrome: current understanding and research prospects.  |  Dan, B. 2009. Epilepsia. 50: 2331-9. PMID: 19874386
7. The C15orf2 gene in the Prader-Willi syndrome region is subject to genomic imprinting and positive selection.  |  Wawrzik, M., et al. 2010. Neurogenetics. 11: 153-61. PMID: 20020165
8. Tyrosinemia type 1 and Angelman syndrome due to paternal uniparental isodisomy 15.  |  Ferrer-Bolufer, I., et al. 2009. J Inherit Metab Dis. 32 Suppl 1: S349-53. PMID: 20033293
9. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis.  |  Rodrigues, G., et al. 2019. Nat Cell Biol. 21: 1403-1412. PMID: 31685984
10. CEMIP as a prognostic biomarker for cancers: a meta- and bioinformatic analysis.  |  Chen, H., et al. 2022. Expert Rev Mol Diagn. 22: 1107-1115. PMID: 36631437
11. Research on the biological mechanism and potential application of CEMIP.  |  Liu, Y., et al. 2023. Front Immunol. 14: 1222425. PMID: 37662915
12. Neuropsychiatric aspects of adult-onset Tay-Sachs disease: two case reports with several new findings.  |  Hurowitz, GI., et al. 1993. J Neuropsychiatry Clin Neurosci. 5: 30-6. PMID: 8428133

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CEMIP Antibody (3C12) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-CEMIP Antibody (3C12) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CEMIP Antibody (3C12) Specifications

Alternate Product Name: CEMIP

Product Clone Name: 3C12

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 880-979

Epitope Target: CEMIP

Epitope Species: human

Product Reactivity/Detection: CEMIP

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for CEMIP Antibody (3C12): N/A